System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Barbara Wollenberg is an expert in Oncology at Rechts der Isar Hospital (Germany). As of October 2026, ScienceLeadR ranks Barbara Wollenberg in the top 1% of experts worldwide for Squamous Cell Carcinoma of Head and Neck and Carcinoma. Barbara Wollenberg has authored 524 publications, the most recent in 2026, and is an investigator in 11 clinical trials, 4 of them ongoing. SLR score: 1,496 (community average: 125). How the SLR is computed.

LeadR Profile

Barbara Wollenberg Rechts der Isar Hospital Germany
1 496 ScienceLeadR Reputation 1496

Unlock

Register Login
Network Map

Oncology

Subspecialties: Otolaryngology - Immunology - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1993 - 2026
Source: PubMed

Technical University of Munich

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 524

Citations

Citations: 7 949 1st author: 15 Last author: 152 Unique author: 9

Main journals

Laryngorhinootologie 124
HNO 74
Anticancer Res 28
Eur Arch Otorhinolaryngol 26
Cancers (Basel) 10

Best Journals

Ann Oncol 1
Cancer Cell 1
Lancet Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
A defined isothiocyanate mixture suppresses platelet signaling and metabolism to limit thrombosis in vivo.
PMID 42876763 — hemorrhage, oxidative stress, platelet aggregation, immune system diseases, calcium, thrombosis, blood platelets, carrageenan, platelet activation		Front Immunol20260
Patient-derived 3D organotypic co-cultures as a long-term ex vivo model for pleomorphic adenoma of the parotid gland.
PMID 42733102 — cells, parotid gland, adenoma, pleomorphic, neoplasms, adenoma, tissues		Sci Rep20260
AI-Assisted Compressed Sensing for Optimized Inner Ear Imaging: a Multi-Rater MRI Evaluation of CSAI T2-DRIVE.
PMID 42704461 — vestibulocochlear nerve, semicircular canals, ear, inner, cochlea, multiple chronic conditions, algorithms, diagnostic imaging		Clin Neuroradiol20260
Centennial CORLAS: Returning to Groningen, Where It All Began.
PMID 42603078		Int Arch Otorhinolaryngol20260
Delineating the CTBP1-Related Phenotypic Spectrum: A Review of HADDTS and Atypical Variants.
PMID 42589715 — registries, seizures		Int J Mol Sci20260

Clinical Studies 11

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 7
Phase 2 4

By status:

Active not recruiting 3
Completed 3
Recruiting 3
Terminated 2

By type:

Interventional 11

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 1
multicentricup10 9

Main Topics

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A phase 3 study to evaluate petosemtamab vs investigator s choice in previously treated metastatic recurrent head and neck cancer
2023-510322-32-00 — cells, safety, carcinoma, squamous cell, neoplasms, squamous cell carcinoma of head and neck, head and neck neoplasms, therapeutics, carcinoma, head, neck		Phase 3Active not recruiting2025
A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first line treatment of head and neck cancer
2023-510323-30-00 — cells, safety, carcinoma, squamous cell, neoplasms, squamous cell carcinoma of head and neck, head and neck neoplasms, therapeutics, carcinoma, head, neck		Phase 3Recruiting2025
European Larynx Organ Preservation Study (ELOS)
2022-502751-61-00 — cells, larynx, organ preservation, docetaxel, induction chemotherapy, carcinoma, squamous cell, laryngectomy, neoplasms, hypopharyngeal neoplasms, biopsy, drug therapy, therapeutics, tissues, chemotherapy, carcinoma		Phase 2Recruiting2024
European Larynx Organ Preservation Study (ELOS) MK 3475 C44
NCT06137378 — cells, laryngeal diseases, disease-free survival, larynx, organ preservation, docetaxel, induction chemotherapy, carcinoma, squamous cell, laryngectomy, laryngeal neoplasms, neoplasms, hypopharyngeal neoplasms, drug therapy, immune checkpoint inhibitors, squamous cell carcinoma of head and neck, neoadjuvant therapy, therapeutics, chemotherapy, carcinoma		Phase 2Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS